



Q Search

Brought to you by Yahoo! Finance

номе	U.S.	BUSINESS	WORLD	ENTERTAIN	IMENT	SPORTS	TECH	POLITICS	SCIENCE H
Busines	s Video	U.S. Econo	omy Sto	ck Markets	Earning	s Opir	ion l	Personal Finance	Press Rele
POPULA	R SEARCH	ES: danica	patrick h	urricane ida	bes sta	ndings	bcs	iran	Q ▼ Sea



UNEMPLOYMENT: October jobs report: A true witches' brew

Experimental Stem Cell Therapy Raises Hope for Pulmonary Fibrosis Patients





RELATED QUOTES							
^DJI	10,023.42	+17.46					
^GSPC	1,069.30	0.00					
AIXIC	2 112 44	0.00					

Tue Nov 3, 2:00 am ET

A bold new approach using adult stem cell therapy has created an international medical first and raised the hope of patients with pulmonary fibrosis, a life threatening disease with as yet no known cure.

Hong Kong (PRWEB) November 3, 2009 -- A bold new approach using adult stem cell therapy has created an international medical first and raised the hope of patients with pulmonary fibrosis, a life threatening disease with as yet no known cure.

Sixty-five year old Spyros Kanelos, a pulmonary fibrosis sufferer who also has emphysema, was given stem cell treatment on the 8th of October in a pioneering 'direct administration' method directed by Professor Demosthenes Bouros at the University Hospital of Alexandoupolis in Greece.

Having tried all available therapies over the past two years and unable to find a suitable donor for a transplant, the patient read of reports of the success of stem cell therapy by Hong Kong based Adistem, a biotechnology company that develops proprietary stem cell technologies for administration that are shared with qualified medical practitioners. Mr Kanelos was especially interested to learn of clinical trials in Asia involving the use of stem cells extracted from the patient's own abdominal fat. Although lung disease was not the subject of the trials, he noted that improvement in the emphysema of seven of the trial patients was observed.

After he contacted Dr Bill Paspaliaris, director of Adistem, the patient was able to arrange for treatment by Professor Demosthenes Bouros, Director of Pulmonary Medicine at the University Hospital of Alexandoupolis and Professor George Koliakos, a stem cell expert from Aristotle University. Initially, the medical team in Greece gave Mr. Kanelos intravenous therapy of his own adipose-derived stem cells. When a slight improvement was seen in the patient's pulmonary function tests Professor Bouros suggested administering the stem cells directly into the lungs, a previously untried method, but one which might give even better results. After receiving institutional ethics approval, the ten minute direct administration procedure was later successfully carried out by bronchoscopy with the patient under local anesthesia.



After he contacted Dr Bill Paspaliaris, director of Adistem, the patient was able to arrange for treatment by Professor Demosthenes Bouros, Director of Pulmonary Medicine at the University Hospital of Alexandoupolis and Professor George Koliakos, a stem cell expert from Aristotle University. Initially, the medical team in Greece gave Mr. Kanelos intravenous therapy of his own adipose-derived stem cells. When a slight improvement was seen in the patient's pulmonary function tests Professor Bouros suggested administering the stem cells directly into the lungs, a previously untried method, but one which might give even better results. After receiving institutional ethics approval, the ten minute direct administration procedure was later successfully carried out by bronchoscopy with the patient under local anesthesia.

Mr Kanelos is now back home with his family in Athens awaiting results of the stem cell therapy due in a few months. Upon interview, Mr. Kanelos said "I hope it works for me, as it will give hope to the thousands of terminal sufferers around the world who cannot get a lung donor". There are five million people worldwide that are affected by idiopathic pulmonary fibrosis. There are over 500,000 patients in the USA alone, where lung transplants are more easily available, and of these, more than 40,000 die from the disease annually.

Said Brian Dardzinski, Adistem Business Manager, "This imaginative approach by Professor Bouros and his team represents another important step forward in adipose-derived stem cell therapy. For pulmonary fibrosis patients around the world it offers the possibility of a life saving procedure. For medicine, it offers a new and possibly effective avenue of treatment for a host of life threatening conditions."

For further information and business queries, please visit "www.Adistem.com"

About Adistern

Adistem is a biotechnology company that discovers, develops and provides to licensed doctors autologous adult adipose-derived stem cell products that address serious medical conditions and assist, in particular, cosmetic and plastic surgery procedures. Adistem owns proprietary technologies that are licensed to major hospitals and world-class clinics.

###

Adistem

Czarina Tablante-Domingo +63.2.8565100


E-mail Information Trackback URL:

http://prweb.com/pingpr.php/Q3Jhcy1Mb3ZILVBpZ2ctRW1wdC1FbXB0LVBpZ2ctWmVybw==






This is the basic Adistem procedure. Extract the fat from the abdomen using mini-lioposcution. Separate the stem cells from the fat. Activate the stem cells using the Adilight-1. Adminster the stem cells to the patient using an IV drip.






Reduction in Stem Cells as we age




35 Million Stem Cells in circulation by age 40.

Stem Cell Therapy increases numbers




Adds millions of stem cells back to circulation





In an individual with no major disease or inflammation the stem cells will spread throughout the body. The lungs will receive the highest percentage of cells.



Example of radio tagging of the stem cells with Emphysema

These radio tagged and activated stem cells were administered via IV drip into the left arm. The stem cells went to the site of the inflammation in the lungs.

5/F CNT Tower 338 Hennessy Road, Wanchai Hong Kong

www.adistem.com